[go: up one dir, main page]

WO2016012965A3 - Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof - Google Patents

Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof Download PDF

Info

Publication number
WO2016012965A3
WO2016012965A3 PCT/IB2015/055572 IB2015055572W WO2016012965A3 WO 2016012965 A3 WO2016012965 A3 WO 2016012965A3 IB 2015055572 W IB2015055572 W IB 2015055572W WO 2016012965 A3 WO2016012965 A3 WO 2016012965A3
Authority
WO
WIPO (PCT)
Prior art keywords
substituted phenyl
acid compounds
alkanoic acid
gpr120
gpr120 agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2015/055572
Other languages
French (fr)
Other versions
WO2016012965A2 (en
Inventor
Sanjay Kumar
Rajiv Sharma
Vijaykumar Bhagwan DEORE
Nilambari Nilkanth Yewalkar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Piramal Enterprises Ltd
Original Assignee
Piramal Enterprises Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Piramal Enterprises Ltd filed Critical Piramal Enterprises Ltd
Priority to US15/328,450 priority Critical patent/US10273230B2/en
Priority to EP15824099.4A priority patent/EP3172185B1/en
Priority to CA2955919A priority patent/CA2955919A1/en
Priority to AU2015293541A priority patent/AU2015293541B2/en
Publication of WO2016012965A2 publication Critical patent/WO2016012965A2/en
Publication of WO2016012965A3 publication Critical patent/WO2016012965A3/en
Priority to IL250255A priority patent/IL250255B/en
Priority to ZA2017/00629A priority patent/ZA201700629B/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
    • C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/20—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hydrogen atoms and substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D309/22—Radicals substituted by oxygen atoms
    • C07D309/24—Methylol radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/16—Radicals substituted by singly bound hetero atoms other than halogen by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10—Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/06—One of the condensed rings being a six-membered aromatic ring the other ring being four-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/14—All rings being cycloaliphatic
    • C07C2602/26—All rings being cycloaliphatic the ring system containing ten carbon atoms
    • C07C2602/28—Hydrogenated naphthalenes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to substituted phenyl alkanoic acid compounds designated as the compound of Formula (I) (as described herein) or a tautomer, a stereoisomer, a geometrical isomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, an N-oxide, a S-oxide or a carboxylic acid isostere thereof; which are GPR120 agonists. The present invention also relates to a pharmaceutical composition of compound of Formula (I) for the treatment of diseases or discorder mediated by GPR120.
PCT/IB2015/055572 2014-07-25 2015-07-23 Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof Ceased WO2016012965A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US15/328,450 US10273230B2 (en) 2014-07-25 2015-07-23 Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
EP15824099.4A EP3172185B1 (en) 2014-07-25 2015-07-23 Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
CA2955919A CA2955919A1 (en) 2014-07-25 2015-07-23 Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
AU2015293541A AU2015293541B2 (en) 2014-07-25 2015-07-23 Substituted phenyl alkanoic acid compounds as GPR120 agonists and uses thereof
IL250255A IL250255B (en) 2014-07-25 2017-01-24 Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
ZA2017/00629A ZA201700629B (en) 2014-07-25 2017-01-25 Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462028891P 2014-07-25 2014-07-25
US62/028,891 2014-07-25

Publications (2)

Publication Number Publication Date
WO2016012965A2 WO2016012965A2 (en) 2016-01-28
WO2016012965A3 true WO2016012965A3 (en) 2016-03-17

Family

ID=55163912

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2015/055572 Ceased WO2016012965A2 (en) 2014-07-25 2015-07-23 Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof

Country Status (7)

Country Link
US (1) US10273230B2 (en)
EP (1) EP3172185B1 (en)
AU (1) AU2015293541B2 (en)
CA (1) CA2955919A1 (en)
IL (1) IL250255B (en)
WO (1) WO2016012965A2 (en)
ZA (1) ZA201700629B (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10227360B2 (en) 2014-02-19 2019-03-12 Piramal Enterprises Limited Compounds for use as GPR120 agonists
US10214521B2 (en) 2014-09-11 2019-02-26 Piramal Enterprises Limited Fused heterocyclic compounds as GPR120 agonists
WO2016125182A1 (en) 2015-02-05 2016-08-11 Piramal Enterprises Limited Compounds containing carbon-carbon linker as gpr120 agonists
US11811623B2 (en) 2016-10-26 2023-11-07 Zscaler, Inc. Deep tracing of user experience
US10728113B2 (en) 2016-10-26 2020-07-28 Zscaler, Inc. Systems and methods for troubleshooting and performance analysis of cloud based services
WO2018107415A1 (en) 2016-12-15 2018-06-21 Merck Sharp & Dohme Corp. Hydroxy isoxazole compounds useful as gpr120 agonists
FI3651766T3 (en) 2017-07-10 2024-11-18 Celgene Corp 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l-oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile as antiproliferative compound
US20210024483A1 (en) 2018-03-06 2021-01-28 Janssen Pharmaceutica Nv Heterocylcoalkenyl derivatives useful as agonists of the gpr120 and / or gpr40
WO2019171277A1 (en) 2018-03-06 2019-09-12 Janssen Pharmaceutica Nv Cylcoalkenyl derivatives useful as agonists of the gpr120 and /or gpr40 receptors
CA3093445A1 (en) 2018-03-08 2019-11-28 Incyte Corporation Aminopyrazine diol compounds as pi3k-.gamma. inhibitors
CN111868035A (en) 2018-03-15 2020-10-30 阿克萨姆股份公司 Substituted pyrazole FFA4/GPR120 receptor agonists
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US12137023B2 (en) 2019-02-25 2024-11-05 Zscaler, Inc. Automatic analysis of user experience issues to reduce resolution time
TW202237119A (en) 2020-12-10 2022-10-01 美商住友製藥腫瘤公司 Alk-5 inhibitors and uses thereof
US11863415B2 (en) 2021-01-14 2024-01-02 Zscaler, Inc. Determining endpoint and application behavior for monitoring user experience
US11949578B2 (en) 2021-01-14 2024-04-02 Zscaler, Inc. Adaptive probing to discover a protocol for network tracing
US11425015B2 (en) 2021-01-14 2022-08-23 Zscaler, Inc. Accurate differential traceroute latency calculation between hops
US11671438B2 (en) 2021-01-14 2023-06-06 Zscaler, Inc. Detection of latency, packet drops, and network hops through a tunnel by tracing hops therein
US11758025B2 (en) 2021-01-14 2023-09-12 Zscaler, Inc. Adaptive tracing using one of a plurality of protocols
US11770319B2 (en) 2021-01-14 2023-09-26 Zscaler, Inc. TCP traceroute using RST and SYN-ACK to determine destination reachability
US11811633B2 (en) 2021-01-14 2023-11-07 Zscaler, Inc. Traceroutes through external proxies
US11637766B2 (en) 2021-01-14 2023-04-25 Zscaler, Inc. Detection of network hops and latency through an opaque tunnel and detection misconfiguration of tunnels
US11784904B2 (en) 2021-01-14 2023-10-10 Zscaler, Inc. Adaptive tracing with a reduced number of probes to avoid firewall issues
US11228519B1 (en) 2021-01-21 2022-01-18 Zscaler, Inc. Detection of latency, packet drops, and network hops through a TCP tunnel using ICMP and UDP probes
US11546240B2 (en) 2021-03-01 2023-01-03 Zscaler, Inc. Proactively detecting failure points in a network
US11563665B2 (en) 2021-03-05 2023-01-24 Zscaler, Inc. Detecting web probes versus regular traffic through a proxy including encrypted traffic
US12438785B2 (en) 2022-06-01 2025-10-07 Zscaler, Inc. Advanced machine learning techniques for internet outage detection
US12028237B2 (en) 2022-06-28 2024-07-02 Zscaler, Inc. Egress handling for networks with public internet protocol (IP) address

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789423A (en) * 1995-12-21 1998-08-04 Pfizer Inc. 3- 5-substituted benzyl)amino!-2-phenylpiperidines as substance P antagonists
WO2010048207A2 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL122317C (en) 1961-07-19
FR1498700A (en) 1965-10-04 1968-01-10
WO2005051373A1 (en) 2003-11-26 2005-06-09 Takeda Pharmaceutical Company Limited Receptor function regulating agent
US7816367B2 (en) 2004-02-27 2010-10-19 Amgen Inc. Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders
US8367708B2 (en) 2006-12-01 2013-02-05 Msd K.K. Phenyl-isoxazol-3-ol derivative
EP2121675A1 (en) 2007-02-22 2009-11-25 Irm Llc Thiazole derivatives as modulators of g protein-coupled receptors
WO2008103501A1 (en) 2007-02-22 2008-08-28 Irm Llc Compounds and methods for modulating g protein-coupled receptors
WO2009038204A1 (en) 2007-09-17 2009-03-26 Pharma Frontier Co., Ltd. Novel long-chain fatty acid derivative compound and g-protein-coupled receptor agonist containing the compound as active ingredient
HRP20120696T1 (en) 2007-10-26 2012-10-31 Japan Tobacco, Inc. Spiro-ring compound and use thereof for medical purposes
AU2009255183A1 (en) 2008-06-02 2009-12-10 Msd K.K. Novel isoxazole derivative
CN102076670B (en) 2008-06-24 2013-05-22 Irm责任有限公司 Compounds and methods for modulating g protein-coupled receptors
AR074760A1 (en) 2008-12-18 2011-02-09 Metabolex Inc GPR120 RECEIVER AGONISTS AND USES OF THE SAME IN MEDICINES FOR THE TREATMENT OF DIABETES AND METABOLIC SYNDROME.
CA2754688A1 (en) 2009-03-11 2010-09-16 Msd K.K. Novel isoindolin-1-one derivative
DE102009033208A1 (en) 2009-07-15 2011-01-20 Merck Patent Gmbh aminopyridine derivatives
WO2011072132A1 (en) 2009-12-09 2011-06-16 The Regents Of The University Of California Methods of treating inflammatory conditions
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2011159297A1 (en) 2010-06-16 2011-12-22 Metabolex, Inc. Gpr120 receptor agonists and uses thereof
JP6259287B2 (en) 2010-10-30 2018-01-10 カインデックス ファーマシューティカルズ インコーポレイテッド 3,4-dihydroxy-2- (3-methylbutanoyl) -5- (3-methylbutyl) -4- (4-methylpentanoyl) cyclopent-2-en-1-one derivative, substantially pure mirror image Isomeric compositions and related applications
MX2014010272A (en) 2012-02-28 2015-08-14 Piramal Entpr Ltd Phenyl alkanoic acid derivatives as gpr agonists.
WO2013139341A1 (en) * 2012-03-20 2013-09-26 Syddansk Universitet Gpr120 receptor modulators
US20140069954A1 (en) 2012-09-07 2014-03-13 Jeffrey Stein Chilled Beverage Dispenser
WO2014059232A2 (en) 2012-10-11 2014-04-17 Merck Sharp & Dohme Corp. Substituted spiropiperidinyl compounds useful as gpr120 agonists
CN104046350B (en) 2013-03-15 2018-08-17 广州熵能创新材料股份有限公司 A kind of fluorescent microsphere and preparation method and application
US10227360B2 (en) 2014-02-19 2019-03-12 Piramal Enterprises Limited Compounds for use as GPR120 agonists
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
US10214521B2 (en) 2014-09-11 2019-02-26 Piramal Enterprises Limited Fused heterocyclic compounds as GPR120 agonists

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789423A (en) * 1995-12-21 1998-08-04 Pfizer Inc. 3- 5-substituted benzyl)amino!-2-phenylpiperidines as substance P antagonists
WO2010048207A2 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof
WO2013185766A1 (en) * 2012-06-15 2013-12-19 Syddansk Universitet Gpr120 receptor modulators

Non-Patent Citations (21)

* Cited by examiner, † Cited by third party
Title
DATABASE CAS 2 December 2011 (2011-12-02), "3-[[[(2S,3S)-2-phenyl-3-piperidinyl]amino]methyl]-4-(2,2,2-trifluoroethoxy)- benzeneacetamide", XP055387337, retrieved from STN Database accession no. 1347559-94-7 *
DATABASE Registry CAS; 1 December 2011 (2011-12-01), "3,4-dihydro-7-[[[(3R,4R)-4-[4-[3-[(2-methoxyphenyl)methoxy]propoxy]phenyl]-3- piperidinyl]oxy]methyl]- 1(2H)-quinolineethanesulfonamide", XP055388013, retrieved from STN Database accession no. 1346947-23-6 *
DATABASE Registry CAS; 11 June 2008 (2008-06-11), "2-[[2-(7-amino-2-naphthalenyl)cyclopentyl]methoxy]-benzenepropanoic acid", XP055387990, retrieved from STN Database accession no. 1027427-54-8 *
DATABASE Registry CAS; 12 June 2008 (2008-06-12), "6-[2-[[2-(3-methoxy-3-oxopropyl)phenoxy]methyl]cyclohexyl]-2- naphthalenecarboxylic acid", XP055387343, retrieved from STN Database accession no. 1027654-19-8 *
DATABASE Registry CAS; 13 February 1996 (1996-02-13), "1 S-(exo,exo)]-2-[[3-[4-[[(4-cyclohexylbutyl)amino]carbonyl]-2-oxazolyl]-7- oxabicyclo[2.2.1]hept-2-yl]methoxy]-benzeneacetic acid", XP055388016, retrieved from STN Database accession no. 173160-56-0 *
DATABASE Registry CAS; 13 June 2008 (2008-06-13), "2-[[2-(7-amino-2-naphthalenyl)cyclopentyl]methoxy]-benzenepropanoic acid methyl ester", XP055387359, retrieved from STN Database accession no. 1027894-93-4 *
DATABASE Registry CAS; 23 February 2014 (2014-02-23), "5-[[[2-(1H-imidazol-1-yl)cyclopentyl]amino]methyl]-2-thiopheneacetic acid", XP055387355, retrieved from STN Database accession no. 1553145-75-7 *
DATABASE Registry CAS; 28 September 2014 (2014-09-28), "methyl 2-(4-(((2-phenyltetrahydro-2H-pyran-3-yl)methyl)amino)-1H-pyrazolo[3,4- d]pyrimidin-1-yl)acetate", XP055388027, retrieved from STN Database accession no. 1627272-79-0 *
DATABASE Registry CAS; 29 April 2011 (2011-04-29), "rel-3-[[[(2R,3 S)-2-(2-fluoro-5-methoxyphenyl)-6-oxo-3-piperidinyl]amino]methyl]- 1H- indole-1-acetamide", XP055388007, retrieved from STN Database accession no. 1287459-87-3 *
DATABASE Registry CAS; 29 April 2011 (2011-04-29), "rel-3-[[[(2R,3 S)-2-(2-fluoro-5-methoxyphenyl)-6-oxo-3-piperidinyl]amino]methyl]-1 H- indole-1-propanamide", XP055387378, retrieved from STN Database accession no. 1287467-25-7 *
DATABASE Registry CAS; 6 June 2008 (2008-06-06), "3-(2-((2-(6-aminonaphthalen-2-yl)cyclopentyl)methoxy)phenyl)propanoic acid", XP055388003, retrieved from STN Database accession no. 1025918-57-3 *
DATABASE Registry CAS; 8 February 2015 (2015-02-08), "N-methyl-4-[[(2-phenylcyclopentyl)amino]methyl]-2-thiazoleacetamide", XP055388021, retrieved from STN Database accession no. 1645359-44-9 *
DATABASE Registry CAS; 8 June 2008 (2008-06-08), "2-[[2-[6-(carboxymethoxy)-2-naphthalenyl]cyclohexyl]methoxy]-benzenepropanoic acid", XP055387950, retrieved from STN Database accession no. 1026475-19-3 *
DATABASE Registry CAS; 8 June 2008 (2008-06-08), "6-[2-[[2-(2-carboxyethyl)phenoxy]methyl]cyclohexyl]-2-naphthalenecarboxylic acid", XP055387944, retrieved from STN Database accession no. 1026500-58-2 *
DATABASE Registry CAS; 8 June 2008 (2008-06-08), "methyl 3-(2-((2-(6-aminonaphthalen-2-yl)cyclopentyl)methoxy)phenyl)propanoate", XP055387348, retrieved from STN Database accession no. 1026489-82-6 *
GUDA, M.R. ET AL.: "An efficient synthesis of styryl 1,3,4-thiadiazoles using Lawesson's reagent and propylphosphonic anhydride-precursors for bis heterocycles", ARABIAN JOURNAL OF CHEMISTRY., vol. 7, 2014, pages 947 - 954, XP055387767, [retrieved on 20140829] *
MARHRAOUI, I. ET AL.: "Synthese de nouveaux glycosyl-1,2,3-triazoles 1,4- disubstitues", J. MAR. CHIM. HETEROCYCL., vol. 9, 2010, pages 59 - 67, XP008185394 *
MURALKIRISHNA, A. ET AL.: "Synthesis, antimicrobial and cytotoxic activities of sulfone linked bis heterocycles", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 54, 2012, pages 605 - 614, XP028932548, DOI: doi:10.1016/j.ejmech.2012.06.014 *
PADMAJA, A. ET AL.: "Synthesis and antimicrobial activity of pyrrolyl/pyrazolyl arylaminosulfonylmethyl 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles", CHEM. PHARM. BULL., vol. 59, 2011, pages 1509 - 1517, XP003032451 *
REDDY, G.M. ET AL.: "Synthesis and antioxidant activity of a new class of mono- and bis-heterocycles", ARCH. PHARM. CHEM. LIFE SCI., vol. 346, 2013, pages 154 - 162, XP055387705 *
REDDY, G.M. ET AL.: "Synthesis and antioxidant activity of styrylsulfonylmethyl 1,3,4- oxadiazoles, pyrazolyl/isoxazolyl-1,3,4-oxadiazoles", CHEM. PHARM. BULL., vol. 61, 2013, pages 1291 - 1297, XP003032450 *

Also Published As

Publication number Publication date
WO2016012965A2 (en) 2016-01-28
EP3172185A4 (en) 2018-01-24
EP3172185B1 (en) 2020-03-04
US20170210731A1 (en) 2017-07-27
ZA201700629B (en) 2021-08-25
IL250255B (en) 2020-11-30
IL250255A0 (en) 2017-03-30
AU2015293541A1 (en) 2017-02-16
US10273230B2 (en) 2019-04-30
CA2955919A1 (en) 2016-01-28
EP3172185A2 (en) 2017-05-31
AU2015293541B2 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
WO2016012965A3 (en) Substituted phenyl alkanoic acid compounds as gpr120 agonists and uses thereof
NZ721645A (en) Compounds for use as gpr120 agonists
WO2015200481A8 (en) Mnk inhibitors and methods related thereto
TN2016000581A1 (en) Heteroaryl compounds useful as inhibitors of sumo activating enzyme
EP4349840A3 (en) Pyrazolopyridine derivative having glp-1 receptor agonist effect
HK1255102A1 (en) Heterocyclic compounds and uses thereof
MX2020003458A (en) Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyrid in-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof.
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
WO2015200680A3 (en) Prmt5 inhibitors and uses thereof
EA032972B1 (en) Heterocyclic carboxylic acids as activators of soluble guanylate cyclase
PH12016501517A1 (en) Tetrazolone-substituted dihydropyridinone mgat2 inhibitors
PH12016502034A1 (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes
HK1206021A1 (en) Novel ring-substituted n-pyridinyl amides as kinase inhibitors
EP4582424A3 (en) 1,2-naphthoquinone derivative and method for preparing same
PH12016502246A1 (en) Carboxamide derivatives
MX2016010973A (en) Aminocarbonylcarbamate compounds.
TN2016000491A1 (en) Carboxamide derivatives.
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
MX2017013099A (en) Methods for the treatment of inflammatory disorders.
WO2015191681A3 (en) Substituted pyridinones as mgat2 inhibitors
MX2016014118A (en) Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes.
MX2018015990A (en) Therapeutic compounds.
WO2013064919A9 (en) Quinazoline derivatives with hsp90 inhibitory activity
WO2016063301A3 (en) Aromatic derivatives as anti-malarial
IN2014MU00072A (en)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15824099

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2955919

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 15328450

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015824099

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 250255

Country of ref document: IL

Ref document number: 2015824099

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2015293541

Country of ref document: AU

Date of ref document: 20150723

Kind code of ref document: A